Common Contracts
5 similar Executive Employment Agreement contracts by Avi Biopharma Inc, Sarepta Therapeutics, Inc.
AVI BIOPHARMA, INC. EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • August 8th, 2013 • Sarepta Therapeutics, Inc. • Pharmaceutical preparations • Washington
This Employment Agreement (the “Agreement”) is entered into as of December 9, 2011 (the “Effective Date”) by and between AVI BioPharma, Inc. (the “Company”), and Jayant Aphale (“Executive”).
SAREPTA THERAPEUTICS, INC. EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • May 9th, 2013 • Sarepta Therapeutics, Inc. • Pharmaceutical preparations • Massachusetts
This Employment Agreement (the “Agreement”) is effective as of January 1, 2013 (the “Effective Date”) by and between Sarepta Therapeutics, Inc., formerly known as AVI BioPharma, Inc. (the “Company”), and Chris Garabedian (“Executive”). This Agreement amends and restates in its entirety that certain employment agreement by and between Executive and the Company dated as of December 17, 2010 (the “Prior Agreement”).
AVI BIOPHARMA, INC. EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • August 8th, 2011 • Avi Biopharma Inc • Pharmaceutical preparations • Washington
This Employment Agreement (the “Agreement”) is entered into as of June 13, 2011 (the “Effective Date”) by and between AVI BioPharma, Inc. (the “Company”), and Edward M. Kaye, M.D. (“Executive”).
AVI BIOPHARMA, INC. EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • May 10th, 2011 • Avi Biopharma Inc • Pharmaceutical preparations • Washington
This Employment Agreement (the “Agreement”) is entered into as of January 10, 2011 (the “Effective Date”) by and between AVI BioPharma, Inc. (the “Company”), and Effie Toshav (“Executive”).
AVI BIOPHARMA, INC. EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • May 10th, 2011 • Avi Biopharma Inc • Pharmaceutical preparations • Washington
This Employment Agreement (the “Agreement”) is entered into as of March 29, 2011 (the “Effective Date”) by and between AVI BioPharma, Inc. (the “Company”), and Peter S. Linsley, Ph.D. (“Executive”).
